NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 230 filers reported holding NEKTAR THERAPEUTICS in Q3 2022. The put-call ratio across all filers is 0.14 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,433,000 | -88.0% | 447,820 | -85.8% | 0.34% | -88.0% |
| Q2 2022 | $11,970,000 | +2120.8% | 3,150,000 | +3050.0% | 2.87% | +2108.5% |
| Q1 2022 | $539,000 | -80.4% | 100,000 | -51.0% | 0.13% | -78.8% |
| Q4 2021 | $2,755,000 | -69.6% | 203,900 | -59.6% | 0.61% | -71.0% |
| Q3 2021 | $9,064,000 | -76.6% | 504,691 | -76.2% | 2.11% | -40.7% |
| Q3 2019 | $38,707,000 | – | 2,125,000 | – | 3.56% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |